deltatrials
Completed PHASE2 NCT00116506

Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer

A Phase II Study of Bevacizumab (Avastin™) and Erlotinib (Tarceva™) in Combination With FOLFOX for Patients With Untreated Metastatic Colorectal Cancer

Sponsor: Beth Israel Deaconess Medical Center

Conditions Colorectal Cancer Neoplasm Metastasis
Interventions FOLFOX bevacizumab erlotinib
Updated 5 times since 2017 Last updated: Dec 19, 2007 Started: Jan 31, 2005 Primary completion: Jul 31, 2007 Completion: Jul 31, 2007

A PHASE2 clinical study on Colorectal Cancer and Neoplasm Metastasis, this trial is completed. The trial is conducted by Beth Israel Deaconess Medical Center and has accumulated 5 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beth Israel Deaconess Medical Center
  • Brigham and Women's Hospital
  • Dana-Farber Cancer Institute
  • Genentech, Inc.
  • Massachusetts General Hospital
  • Sanofi-Synthelabo
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States